Health
Making a Weight-Loss Pill Won’t Be Easy, Pfizer Data Shows
- High side effect rates seen in mid-stage study; shares tumble
- Result hurts efforts to make up for gap left by pandemic
This article is for subscribers only.
Pfizer Inc.’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy.
The New York drugmaker dropped development of a twice-daily version of its danuglipron obesity pill due to nausea and vomiting, according to a statement Friday. The shares fell as much as 7.1%, their biggest intraday loss in more than three years, as of 11:06 a.m. in New York.